Literature DB >> 32572978

Method for Successfully Inducting Individuals Who Use Illicit Fentanyl Onto Buprenorphine/Naloxone.

Denis Antoine1, Andrew S Huhn1, Eric C Strain1, Gavin Turner1, Jasmyne Jardot1, Alexis S Hammond1, Kelly E Dunn1.   

Abstract

BACKGROUND AND OBJECTIVES: Individuals exposed to fentanyl are at risk of precipitated withdrawal using typical buprenorphine/naloxone induction procedures.
METHODS: This case series describes buprenorphine/naloxone inductions of four individuals who tested positive for fentanyl.
RESULTS: Buprenorphine-precipitated withdrawal was observed in two individuals who completed a conventional buprenorphine/naloxone induction strategy. Two more individuals completed a revised buprenorphine/naloxone induction strategy that did not precipitate withdrawal. DISCUSSION AND
CONCLUSION: Using multiple 2 mg doses of buprenorphine/naloxone in patients already in mild/moderate withdrawal improved outcomes. SCIENTIFIC SIGNIFICANCE: Persons who use illicit fentanyl might be less likely to experience precipitated withdrawal from this revised buprenorphine/naloxone induction strategy. (Am J Addict 2021;30:83-87).
© 2020 American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32572978      PMCID: PMC7755703          DOI: 10.1111/ajad.13069

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  19 in total

1.  Solubility and related physicochemical properties of narcotic analgesics.

Authors:  S D Roy; G L Flynn
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

2.  What should clinicians do as fentanyl replaces heroin?

Authors:  Adam Bisaga
Journal:  Addiction       Date:  2019-01-20       Impact factor: 6.526

3.  Factors associated with complicated buprenorphine inductions.

Authors:  Susan D Whitley; Nancy L Sohler; Hillary V Kunins; Angela Giovanniello; Xuan Li; Galit Sacajiu; Chinazo O Cunningham
Journal:  J Subst Abuse Treat       Date:  2010-07

4.  Clinical actions of fentanyl and buprenorphine. The significance of receptor binding.

Authors:  R A Boas; J W Villiger
Journal:  Br J Anaesth       Date:  1985-02       Impact factor: 9.166

Review 5.  Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment.

Authors:  Sandra D Comer; Catherine M Cahill
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

6.  Rapid micro-induction of buprenorphine/naloxone for opioid use disorder in an inpatient setting: A case series.

Authors:  Sukhpreet Klaire; Rebecca Zivanovic; Skye Pamela Barbic; Raman Sandhu; Nickie Mathew; Pouya Azar
Journal:  Am J Addict       Date:  2019-03-22

Review 7.  Buprenorphine: how to use it right.

Authors:  Rolley E Johnson; Eric C Strain; Leslie Amass
Journal:  Drug Alcohol Depend       Date:  2003-05-21       Impact factor: 4.492

8.  Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument.

Authors:  D Andrew Tompkins; George E Bigelow; Joseph A Harrison; Rolley E Johnson; Paul J Fudala; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2009-08-03       Impact factor: 4.492

Review 9.  The Clinical Opiate Withdrawal Scale (COWS).

Authors:  Donald R Wesson; Walter Ling
Journal:  J Psychoactive Drugs       Date:  2003 Apr-Jun

10.  Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder.

Authors:  Jan Gryczynski; Helen Nichols; Robert P Schwartz; Shannon Gwin Mitchell; Paulette Hill; Kim Wireman
Journal:  Drug Alcohol Depend       Date:  2019-08-30       Impact factor: 4.492

View more
  12 in total

1.  Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: A case series.

Authors:  Daniel Shearer; Samantha Young; Nadia Fairbairn; Rupinder Brar
Journal:  Drug Alcohol Rev       Date:  2021-10-13

2.  Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine.

Authors:  Susan L Calcaterra; Marlene Martin; Richard Bottner; Honora Englander; Zoe Weinstein; Melissa B Weimer; Eugene Lambert; Shoshana J Herzig
Journal:  J Hosp Med       Date:  2022-07-26       Impact factor: 2.899

3.  Evidence of Buprenorphine-precipitated Withdrawal in Persons Who Use Fentanyl.

Authors:  Neil B Varshneya; Ashish P Thakrar; J Gregory Hobelmann; Kelly E Dunn; Andrew S Huhn
Journal:  J Addict Med       Date:  2021-11-23       Impact factor: 4.647

4.  "Just give them a choice": Patients' perspectives on starting medications for opioid use disorder in the ED.

Authors:  Elizabeth M Schoenfeld; Lauren M Westafer; Samantha A Beck; Benjamin G Potee; Sravanthi Vysetty; Caty Simon; Jillian M Tozloski; Abigail L Girardin; William E Soares
Journal:  Acad Emerg Med       Date:  2022-05-16       Impact factor: 5.221

5.  Low-dose Buprenorphine Initiation in Hospitalized Adults With Opioid Use Disorder: A Retrospective Cohort Analysis.

Authors:  Dana Button; Jennifer Hartley; Jonathan Robbins; Ximena A Levander; Natashia J Smith; Honora Englander
Journal:  J Addict Med       Date:  2022 Mar-Apr 01       Impact factor: 3.702

6.  Associations between fentanyl use and initiation, persistence, and retention on medications for opioid use disorder among people living with uncontrolled HIV disease.

Authors:  Ryan R Cook; Randy Torralva; Caroline King; Paula J Lum; Hansel Tookes; Canyon Foot; Pamela Vergara-Rodriguez; Allan Rodriguez; Laura Fanucchi; Gregory M Lucas; Elizabeth N Waddell; P Todd Korthuis
Journal:  Drug Alcohol Depend       Date:  2021-09-20       Impact factor: 4.492

7.  Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder.

Authors:  August F Holtyn; Forrest Toegel; Matthew D Novak; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman
Journal:  Drug Alcohol Depend       Date:  2021-05-27       Impact factor: 4.852

Review 8.  The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder.

Authors:  Joao P De Aquino; Suprit Parida; Mehmet Sofuoglu
Journal:  Clin Drug Investig       Date:  2021-04-05       Impact factor: 2.859

9.  The discounting of death: Probability discounting of heroin use by fatal overdose likelihood and drug purity.

Authors:  Sean B Dolan; Matthew W Johnson; Kelly E Dunn; Andrew S Huhn
Journal:  Exp Clin Psychopharmacol       Date:  2021-06       Impact factor: 3.492

10.  Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia.

Authors:  Antoine Chaillon; Chrianna Bharat; Jack Stone; Nicola Jones; Louisa Degenhardt; Sarah Larney; Michael Farrell; Peter Vickerman; Matthew Hickman; Natasha K Martin; Annick Bórquez
Journal:  Addiction       Date:  2021-12-04       Impact factor: 7.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.